Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Raised to "Hold" at Wall Street Zen

Monopar Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Monopar Therapeutics from “sell” to “hold.” Across analysts, the stock has a “Moderate Buy” consensus rating and an average price target of $123.12.
  • Shares opened at $69.00 and were down 1.8%; the stock’s reported 12-month range is $50.07 to $124.82.
  • Monopar reported quarterly EPS of -$0.72, matching analyst expectations. Insiders sold 51,920 shares worth about $4.53 million over the past 90 days; the sales were made under pre-arranged trading plans.
  • Five stocks we like better than Monopar Therapeutics.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

MNPR has been the subject of a number of other reports. Cantor Fitzgerald upgraded shares of Monopar Therapeutics from a "neutral" rating to an "overweight" rating and set a $119.00 price objective for the company in a research report on Thursday, November 12th. Zacks Research downgraded shares of Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 13th. Morgan Stanley raised their target price on shares of Monopar Therapeutics from $130.00 to $133.00 and gave the company an "overweight" rating in a research report on Monday, November 16th. HC Wainwright reaffirmed a "buy" rating on shares of Monopar Therapeutics in a research note on Thursday, November 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $123.12.

Check Out Our Latest Analysis on Monopar Therapeutics

Monopar Therapeutics Trading Down 1.8%

Monopar Therapeutics stock opened at $69.00 on Friday. Monopar Therapeutics has a 12-month low of $50.07 and a 12-month high of $124.82. The business's 50-day moving average price is $78.36 and its two-hundred day moving average price is $77.53.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.72) EPS for the quarter, hitting analysts' consensus estimates of ($0.72). As a group, equities research analysts forecast that Monopar Therapeutics will post -2.64 EPS for the current year.

Insider Transactions at Monopar Therapeutics

In other news, Director Christopher M. Starr sold 8,400 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $78.50, for a total value of $659,400.00. Following the completion of the transaction, the director owned 5,173 shares of the company's stock, valued at $406,080.50. This represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the company's stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the transaction, the chief executive officer directly owned 99,267 shares of the company's stock, valued at $8,735,496. This represents a 22.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 51,920 shares of company stock valued at $4,527,913. Company insiders own 9.70% of the company's stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in MNPR. American Century Companies Inc. lifted its holdings in shares of Monopar Therapeutics by 127.1% during the third quarter. American Century Companies Inc. now owns 5,606 shares of the company's stock worth $447,000 after purchasing an additional 3,137 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Monopar Therapeutics by 443.8% in the third quarter. Goldman Sachs Group Inc. now owns 87,877 shares of the company's stock worth $7,001,000 after purchasing an additional 71,716 shares during the last quarter. State Street Corp grew its stake in shares of Monopar Therapeutics by 24.1% in the third quarter. State Street Corp now owns 229,771 shares of the company's stock worth $18,306,000 after purchasing an additional 44,669 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in Monopar Therapeutics by 18.9% in the third quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company's stock valued at $132,000 after purchasing an additional 262 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Monopar Therapeutics in the second quarter valued at $7,124,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

Featured Articles

Analyst Recommendations for Monopar Therapeutics (NASDAQ:MNPR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Monopar Therapeutics Right Now?

Before you consider Monopar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.

While Monopar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines